Astera Labs, Inc. $ALAB Position Boosted by Rhumbline Advisers

Rhumbline Advisers lifted its holdings in Astera Labs, Inc. (NASDAQ:ALAB) by 51.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 157,884 shares of the company’s stock after purchasing an additional 53,539 shares during the period. Rhumbline Advisers owned about 0.09% of Astera Labs worth $14,276,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Alliancebernstein L.P. boosted its holdings in Astera Labs by 114.2% during the first quarter. Alliancebernstein L.P. now owns 8,401,019 shares of the company’s stock worth $501,289,000 after buying an additional 4,478,741 shares in the last quarter. Atreides Management LP boosted its stake in shares of Astera Labs by 153.3% during the 1st quarter. Atreides Management LP now owns 4,652,264 shares of the company’s stock worth $277,601,000 after acquiring an additional 2,815,614 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Astera Labs by 29.6% in the 2nd quarter. Vanguard Group Inc. now owns 12,049,223 shares of the company’s stock worth $1,089,491,000 after acquiring an additional 2,751,747 shares during the last quarter. FengHe Fund Management Pte. Ltd. acquired a new position in shares of Astera Labs in the 2nd quarter worth $106,772,000. Finally, Bank of Nova Scotia raised its position in shares of Astera Labs by 3,742.2% during the first quarter. Bank of Nova Scotia now owns 964,400 shares of the company’s stock worth $57,546,000 after purchasing an additional 939,300 shares during the period. 60.47% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ALAB. Weiss Ratings reiterated a “hold (c-)” rating on shares of Astera Labs in a research report on Wednesday, October 8th. Bank of America began coverage on shares of Astera Labs in a report on Friday, October 3rd. They issued a “neutral” rating and a $230.00 target price for the company. Morgan Stanley lifted their target price on shares of Astera Labs from $200.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Wall Street Zen downgraded shares of Astera Labs from a “buy” rating to a “hold” rating in a research report on Tuesday, November 11th. Finally, Stifel Nicolaus raised their price objective on shares of Astera Labs from $185.00 to $200.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, Astera Labs presently has an average rating of “Moderate Buy” and an average price target of $187.06.

Astera Labs Stock Performance

ALAB stock opened at $157.54 on Friday. The firm has a 50 day simple moving average of $175.95 and a 200 day simple moving average of $148.90. Astera Labs, Inc. has a 52 week low of $47.13 and a 52 week high of $262.90. The stock has a market cap of $26.61 billion, a P/E ratio of 141.92, a P/E/G ratio of 2.94 and a beta of 1.37.

Astera Labs (NASDAQ:ALAB) last released its earnings results on Tuesday, November 4th. The company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.10. The company had revenue of $230.58 million during the quarter, compared to the consensus estimate of $206.42 million. Astera Labs had a net margin of 27.50% and a return on equity of 13.48%. The company’s revenue was up 103.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.23 EPS. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. Sell-side analysts predict that Astera Labs, Inc. will post 0.34 EPS for the current year.

Insider Buying and Selling at Astera Labs

In other Astera Labs news, COO Sanjay Gajendra sold 90,459 shares of the business’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $144.69, for a total value of $13,088,512.71. Following the transaction, the chief operating officer owned 1,599,750 shares in the company, valued at $231,467,827.50. The trade was a 5.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel Philip Mazzara sold 4,620 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $144.69, for a total value of $668,467.80. Following the completion of the transaction, the general counsel directly owned 147,040 shares in the company, valued at approximately $21,275,217.60. The trade was a 3.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 586,936 shares of company stock valued at $90,628,610 in the last quarter. Corporate insiders own 12.50% of the company’s stock.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.